JP2009511014A5 - - Google Patents

Download PDF

Info

Publication number
JP2009511014A5
JP2009511014A5 JP2008534644A JP2008534644A JP2009511014A5 JP 2009511014 A5 JP2009511014 A5 JP 2009511014A5 JP 2008534644 A JP2008534644 A JP 2008534644A JP 2008534644 A JP2008534644 A JP 2008534644A JP 2009511014 A5 JP2009511014 A5 JP 2009511014A5
Authority
JP
Japan
Prior art keywords
self
vector
enhancer
composition
polypeptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2008534644A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009511014A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2006/038776 external-priority patent/WO2007044394A2/en
Publication of JP2009511014A publication Critical patent/JP2009511014A/ja
Publication of JP2009511014A5 publication Critical patent/JP2009511014A5/ja
Pending legal-status Critical Current

Links

JP2008534644A 2005-10-05 2006-10-04 自己免疫疾患の処置のための組成物および方法 Pending JP2009511014A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US72420305P 2005-10-05 2005-10-05
PCT/US2006/038776 WO2007044394A2 (en) 2005-10-05 2006-10-04 Compositions and methods for treatment of autoimmune disease

Publications (2)

Publication Number Publication Date
JP2009511014A JP2009511014A (ja) 2009-03-19
JP2009511014A5 true JP2009511014A5 (enExample) 2010-12-16

Family

ID=37943343

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2008534644A Pending JP2009511014A (ja) 2005-10-05 2006-10-04 自己免疫疾患の処置のための組成物および方法

Country Status (9)

Country Link
US (1) US20100160415A1 (enExample)
EP (1) EP1931390B1 (enExample)
JP (1) JP2009511014A (enExample)
CN (1) CN101365494A (enExample)
AU (1) AU2006302477A1 (enExample)
CA (1) CA2624615A1 (enExample)
IL (1) IL190520A0 (enExample)
NZ (1) NZ567150A (enExample)
WO (1) WO2007044394A2 (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3428257B1 (en) 2003-09-29 2023-06-14 Deb IP Limited High alcohol content gel-like and foaming compositions
DE102004062775A1 (de) 2004-12-21 2006-06-29 Stockhausen Gmbh Alkoholischer Pumpschaum
CN103417388A (zh) 2005-03-07 2013-12-04 戴博全球保健有限公司 含有有机硅表面活性剂的高醇含量发泡组合物
WO2010151420A1 (en) * 2009-06-05 2010-12-29 Bayhill Therapeutics, Inc. Compositions and methods for treatment of insulin-dependent diabetes mellitus
WO2011091138A1 (en) * 2010-01-20 2011-07-28 Bayhill Therapeutics, Inc. Combination therapy to treat autoimmune diseases
CN103562386A (zh) * 2011-05-25 2014-02-05 国立大学法人冈山大学 Reic表达腺病毒载体
KR101466875B1 (ko) * 2012-05-11 2014-12-03 가톨릭대학교 산학협력단 항종양괴사인자 수용체 2를 발현하도록 설계된 미니서클 벡터를 이용한 자가면역질환 치료
KR101466874B1 (ko) * 2012-05-11 2014-12-03 가톨릭대학교 산학협력단 자가면역 질환의 예방과 치료를 위한 ｉｌ-６ 수용체에 대한 항체를 발현하는 미니서클
ES2719691T3 (es) 2013-11-22 2019-07-12 Amarna Holding B V Procedimiento de restauración de tolerancia inmunitaria in vivo
US20160320384A1 (en) * 2013-12-31 2016-11-03 Yeda Research And Development Co. Ltd. Methods for assaying immunological competence
EP3090064B1 (en) 2013-12-31 2019-11-13 Yeda Research and Development Co. Ltd. Diagnosis of systemic lupus erythematosus using oligonucleotides antigens
US12605432B2 (en) 2014-06-04 2026-04-21 Diamyd Medical Ab Combinations for antigen based therapy
SMT202000384T1 (it) * 2014-06-04 2020-09-10 Diamyd Medical Ab Acido glutammico decarbossilasi(gad)per l'uso nel trattamento di una malattia autoimmune
US11047855B2 (en) 2015-03-01 2021-06-29 Immunarray Ltd. Diagnosis of systemic lupus erythematosus using protein, peptide and oligonucleotide antigens
WO2017222911A1 (en) * 2016-06-20 2017-12-28 The Board Of Trustees Of The Leland Stanford Junior University Circular rnas and their use in immunomodulation
RU2752608C2 (ru) 2016-11-01 2021-07-29 Ново Нордиск А/С Толерогенная днк-вакцина
BR112020026606A2 (pt) * 2018-06-25 2021-04-06 Akouos, Inc. Métodos de tratamento de perda auditiva e/ou perda de visão associada à clrn1
US11279745B2 (en) 2019-04-26 2022-03-22 Novo Nordisk A/S Tolerogenic DNA vaccine

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6274136B1 (en) * 1996-05-29 2001-08-14 University Of Southern California Construction and use of genes encoding pathogenic epitopes for treatment of autoimmune disease
EP1094844A4 (en) * 1998-07-09 2005-01-12 Merck & Co Inc VACCINE FORMULATIONS BASED ON POLYNUCLEOTIDES
US6355271B1 (en) * 1999-02-03 2002-03-12 Biosante Pharmaceuticals, Inc. Therapeutic calcium phosphate particles and methods of manufacture and use
US7030098B2 (en) * 1999-03-12 2006-04-18 The Board Of Trustees Of The Leland Stanford Junior University DNA vaccination for treatment of autoimmune disease
US6479474B2 (en) * 1999-07-08 2002-11-12 Wisconsin Alumni Research Foundation Dietary calcium as a supplement to vitamin D compound treatment of multiple sclerosis
WO2003011118A2 (en) * 2001-08-02 2003-02-13 Trinity Biomedical Technology Corporation Human zona pellucida proteins and methods of their use in diagnosing male infertility
JP2005510533A (ja) * 2001-11-21 2005-04-21 ザ ボード オブ トラスティーズ オブ レランド スタンフォード ジュニア ユニバーシティ ポリヌクレオチド療法
CA2480634A1 (en) * 2002-03-29 2003-10-09 The Board Of Trustees Of The Leland Stanford Junior University Use of statins and other immunomodulatory agents in the treatment of autoimmune disease
WO2005035771A2 (en) * 2003-10-10 2005-04-21 Powderject Vaccines, Inc. Nucleic acid constructs

Similar Documents

Publication Publication Date Title
Beaton et al. The membrane trafficking protein calpactin forms a complex with bluetongue virus protein NS3 and mediates virus release
Lamm et al. Non-snRNP protein splicing factors
JP6272907B2 (ja) 代謝障害の処置における組成物及び使用方法
Zhang et al. Transcription and identification of an envelope protein gene (p22) from shrimp white spot syndrome virus
JP2020514286A5 (enExample)
IL319481A (en) Variants of acid alpha-glucosidase and their uses
JP2017512466A5 (enExample)
JP2004254697A (ja) 殺菌／浸透性が向上した安定なタンパク質生成物およびそれを含む薬剤組成物
JP2007297407A5 (enExample)
JP2011501652A5 (enExample)
JP2023535121A5 (enExample)
EP3943512A1 (en) Fusion protein for enhancing gene editing and use thereof
JP2009523007A5 (enExample)
JP2026034616A (ja) 糖尿病を処置するための修飾型インスリンおよびグルコキナーゼ核酸
WO2009031835A4 (en) Cell permeable nm23 recombinant proteins, polynucleotides encoding the same, and anti-metastatic composition comprising the same
Tulalamba et al. Distinct transduction of muscle tissue in mice after systemic delivery of AAVpo1 vectors
Merle et al. Perspectives for gene therapy of Wilson disease
ATE501256T1 (de) Rekombinantes protein mit krebsunterdrückender wirkung, sein codierendes gen und seine verwendung
JP2018536432A5 (enExample)
WO2019000093A1 (en) PLATINUM TALE AND USE THEREOF TO INCREASE THE EXPRESSION OF FRATAXIN
KR101756131B1 (ko) 간세포 성장인자 및 기질세포 유발인자1알파를 이용한 말초동맥질환의 예방 또는 치료용 조성물
JP2020535203A5 (enExample)
Zelník et al. Structure and properties of a herpesvirus of turkeys recombinant in which US1, US10 and SORF3 genes have been replaced by a lacZ expression cassette
Guo et al. Transcriptional suppression of IE180 and TK promoters by the EP0 of pseudorabies virus strains Ea and Fa
Muramatsu et al. Transcription-positive cofactor 4 enhances rescue of adeno-associated virus genome from an infectious clone